Key result
Therapeutic-dose DOACs increase major bleeding ~66% without reducing recurrent VTE compared to low doses.
Why the study?
Does low dose DOAC therapy improve safety without compromising efficacy compared to therapeutic dose DOACs in patients requiring extended secondary prophylaxis of VTE?
Meta-Analysis (n=8,781)
Does low dose DOAC therapy improve safety without compromising efficacy compared to therapeutic dose DOACs in patients requiring extended secondary prophylaxis of VTE?
Answers are grounded in this paper and cite their sources.
Low-dose DOACs offer a safer bleeding profile with comparable efficacy to therapeutic doses for the extended secondary prevention of VTE.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kounoudi et al. (2026) conducted a meta-analysis in venous thromboembolism (VTE) (n=8,781). Low dose direct oral anticoagulants (DOACs) vs. Therapeutic dose DOACs was evaluated on recurrent VTE (RR 0.97, 95% CI 0.70 - 1.34, p=.86). Therapeutic doses of DOACs did not reduce recurrent VTE compared to low doses but increased major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: